1. Home
  2. BRIA vs VTGN Comparison

BRIA vs VTGN Comparison

Compare BRIA & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRIA
  • VTGN
  • Stock Information
  • Founded
  • BRIA 2011
  • VTGN 1998
  • Country
  • BRIA Singapore
  • VTGN United States
  • Employees
  • BRIA N/A
  • VTGN N/A
  • Industry
  • BRIA
  • VTGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • BRIA
  • VTGN Health Care
  • Exchange
  • BRIA NYSE
  • VTGN Nasdaq
  • Market Cap
  • BRIA 86.3M
  • VTGN 82.7M
  • IPO Year
  • BRIA 2024
  • VTGN N/A
  • Fundamental
  • Price
  • BRIA $2.99
  • VTGN $2.81
  • Analyst Decision
  • BRIA
  • VTGN
  • Analyst Count
  • BRIA 0
  • VTGN 0
  • Target Price
  • BRIA N/A
  • VTGN N/A
  • AVG Volume (30 Days)
  • BRIA 28.9K
  • VTGN 189.5K
  • Earning Date
  • BRIA 02-19-2025
  • VTGN 02-13-2025
  • Dividend Yield
  • BRIA N/A
  • VTGN N/A
  • EPS Growth
  • BRIA N/A
  • VTGN N/A
  • EPS
  • BRIA 92.24
  • VTGN N/A
  • Revenue
  • BRIA $55,755,669.00
  • VTGN $876,000.00
  • Revenue This Year
  • BRIA N/A
  • VTGN N/A
  • Revenue Next Year
  • BRIA N/A
  • VTGN N/A
  • P/E Ratio
  • BRIA $0.03
  • VTGN N/A
  • Revenue Growth
  • BRIA 8.03
  • VTGN 8.08
  • 52 Week Low
  • BRIA $3.16
  • VTGN $2.22
  • 52 Week High
  • BRIA $4.38
  • VTGN $5.74
  • Technical
  • Relative Strength Index (RSI)
  • BRIA N/A
  • VTGN 45.62
  • Support Level
  • BRIA N/A
  • VTGN $2.81
  • Resistance Level
  • BRIA N/A
  • VTGN $3.04
  • Average True Range (ATR)
  • BRIA 0.00
  • VTGN 0.16
  • MACD
  • BRIA 0.00
  • VTGN -0.02
  • Stochastic Oscillator
  • BRIA 0.00
  • VTGN 27.03

About BRIA BRILLIA INC

BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Share on Social Networks: